The spread of β-lactamases that hydrolyze penicillins, cephalosporins and carbapenems among Gram-negative bacteria has limited options for treating bacterial infections. Initially, Klebsiella pneumoniae carbapenemase-2 (KPC-2) emerged as a widespread carbapenem hydrolyzing β-lactamase that also hydrolyzes penicillins and cephalosporins but not cephamycins and ceftazidime. In recent years, single and double amino acid substitution variants of KPC-2 have emerged among clinical isolates that show increased resistance to ceftazidime. Because it confers multi-drug resistance, KPC β-lactamase is a threat to public health. In this study, the evolution of KPC-2 function was determined in nine clinically isolated variants by examining the effects of the substitutions on enzyme kinetic parameters, protein stability and antibiotic resistance profile. The results indicate that the amino acid substitutions associated with KPC-2 natural variants lead to increased catalytic efficiency for ceftazidime hydrolysis and a consequent increase in ceftazidime resistance. Single substitutions lead to modest increases in catalytic activity while the double mutants exhibit significantly increased ceftazidime hydrolysis and resistance levels. The P104R, V240G and H274Y substitutions in single and double mutant combinations lead to the largest increases in ceftazidime hydrolysis and resistance. Molecular modeling suggests that the P104R and H274Y mutations could facilitate ceftazidime hydrolysis through increased hydrogen bonding interactions with the substrate while the V240G substitution may enhance backbone flexibility so that larger substrates might be accommodated in the active site. Additionally, we observed a strong correlation between gain of catalytic function for ceftazidime hydrolysis and loss of enzyme stability, which is in agreement with the ‘stability-function tradeoff’ phenomenon. The high Tm of KPC-2 (66.5°C) provides an evolutionary advantage as compared to other class A enzymes such as TEM (51.5°C) and CTX-M (51°C) in that it can acquire multiple destabilizing substitutions without losing the ability to fold into a functional enzyme.
References
[1]
Livermore DM, Woodford N. The β-lactamase threat in Enterobacteriaceae, Pseudomonas and Acinetobacter. Trends Microbiol. 2006;14: 413–420. pmid:16876996 doi: 10.1016/j.tim.2006.07.008
[2]
Arias CA, Murray BE. Antibiotic-Resistant Bugs in the 21st Century—A Clinical Super-Challenge. N Engl J Med. 2009;360: 439–443. doi: 10.1056/NEJMp0804651. pmid:19179312
[3]
Kong KF, Schneper L, Mathee K. Beta-lactam antibiotics: from antibiosis to resistance and bacteriology. APMIS. 2010;118: 1–36. doi: 10.1111/j.1600-0463.2009.02563.x. pmid:20041868
[4]
Papp-Wallace KM, Endimiani A, Taracila MA, Bonomo RA. Carbapenems: Past, Present, and Future. Antimicrob Agents Chemother. 2011;55: 4943–4960. doi: 10.1128/AAC.00296-11. pmid:21859938
[5]
Birnbaum J, Kahan FM, Kropp H, MacDonald JS. Carbapenems, a new class of beta-lactam antibiotics. Discovery and development of imipenem/cilastatin. Am J Med. 1985;78: 3–21. pmid:3925777 doi: 10.1016/0002-9343(85)90097-x
[6]
Maveyraud L, Mourey L, Kotra LP, Pedelacq J-D, Guillet V, Mobashery S, et al. Structural Basis for Clinical Longevity of Carbapenem Antibiotics in the Face of Challenge by the Common Class A β-Lactamases from the Antibiotic-Resistant Bacteria. J Am Chem Soc. 1998;120: 9748–9752. doi: 10.1021/ja9818001
[7]
Nukaga M, Bethel CR, Thomson JM, Hujer AM, Distler A, Anderson VE, et al. Inhibition of class A β-lactamases by carbapenems: crystallographic observation of two conformations of meropenem in SHV-1. J Am Chem Soc. 2008;130: 12656–12662. doi: 10.1021/ja7111146. pmid:18761444
[8]
Fonseca F, Chudyk EI, van der Kamp MW, Correia A, Mulholland AJ, Spencer J. The basis for carbapenem hydrolysis by class A β-lactamases: a combined investigation using crystallography and simulations. J Am Chem Soc. 2012;134: 18275–18285. doi: 10.1021/ja304460j. pmid:23030300
[9]
Helfand MS, Bonomo RA. β-lactamases: a survey of protein diversity. Curr Drug Targets Infect Disord. 2003;3: 9–23. pmid:12570729 doi: 10.2174/1568005033342181
[10]
Crowder MW, Spencer J, Vila AJ. Metallo-β-lactamases: novel weaponry for antibiotic resistance in bacteria. Acc Chem Res. 2006;39: 721–728. pmid:17042472 doi: 10.1021/ar0400241
[11]
Pfeifer Y, Cullik A, Witte W. Resistance to cephalosporins and carbapenems in Gram-negative bacterial pathogens. Int J Med Microbiol. 2010;300: 371–379. doi: 10.1016/j.ijmm.2010.04.005. pmid:20537585
[12]
Walsh TR. Emerging carbapenemases: a global perspective. Int J Antimicrob Agents. 2010;36 Suppl 3: S8–14. doi: 10.1016/S0924-8579(10)70004-2. pmid:21129630
[13]
Bush K, Fisher JF. Epidemiological expansion, structural studies, and clinical challenges of new β-lactamases from gram-negative bacteria. Annu Rev Microbiol. 2011;65: 455–478. doi: 10.1146/annurev-micro-090110-102911. pmid:21740228
[14]
Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis. 2009;9: 228–236. doi: 10.1016/S1473-3099(09)70054-4. pmid:19324295
[15]
Naas T, Cuzon G, Villegas MV, Lartigue MF, Quinn JP, Nordmann P. Genetic structures at the origin of acquisition of the β-lactamase blaKPC gene. Antimicrob Agents Chemother. 2008;52: 1257–1263. doi: 10.1128/AAC.01451-07. pmid:18227185
[16]
Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, et al. Novel carbapenem-hydrolyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother. 2001;45: 1151–1161. pmid:11257029 doi: 10.1128/aac.45.4.1151-1161.2001
[17]
Hidalgo-Grass C, Warburg G, Temper V, Benenson S, Moses AE, Block C, et al. KPC-9, a novel carbapenemase from clinical specimens in Israel. Antimicrob Agents Chemother. 2012;56: 6057–6059. doi: 10.1128/AAC.01156-12. pmid:22964247
[18]
Lamoureaux TL, Frase H, Antunes NT, Vakulenko SB. Antibiotic resistance and substrate profiles of the class A carbapenemase KPC-6. Antimicrob Agents Chemother. 2012;56: 6006–6008. doi: 10.1128/AAC.01338-12. pmid:22908150
[19]
Lascols C, Hackel M, Hujer AM, Marshall SH, Bouchillon SK, Hoban DJ, et al. Using nucleic acid microarrays to perform molecular epidemiology and detect novel β-lactamases: a snapshot of extended-spectrum β-lactamases throughout the world. J Clin Microbiol. 2012;50: 1632–1639. doi: 10.1128/JCM.06115-11. pmid:22322349
[20]
Robledo IE, Aquino EE, Sante MI, Santana JL, Otero DM, Leon CF, et al. Detection of KPC in Acinetobacter spp. in Puerto Rico. Antimicrob Agents Chemother. 2010;54: 1354–1357. doi: 10.1128/AAC.00899-09. pmid:20038618
[21]
Wolter DJ, Kurpiel PM, Woodford N, Palepou MF, Goering RV, Hanson ND. Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4. Antimicrob Agents Chemother. 2009;53: 557–562. doi: 10.1128/AAC.00734-08. pmid:19015357
[22]
Woodford N, Tierno PM Jr., Young K, Tysall L, Palepou MF, Ward E, et al. Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A β-lactamase, KPC-3, in a New York Medical Center. Antimicrob Agents Chemother. 2004;48: 4793–4799. pmid:15561858 doi: 10.1128/aac.48.12.4793-4799.2004
[23]
Adamski CJ, Cardenas AM, Brown NG, Horton LB, Sankaran B, Prasad BV, et al. Molecular Basis for the Catalytic Specificity of the CTX-M Extended-Spectrum β-Lactamases. Biochemistry. 2014;54: 447–458. doi: 10.1021/bi501195g. pmid:25489790
[24]
Wells JA. Additivity of mutational effects in proteins. Biochemistry. 1990;29: 8509–8517. pmid:2271534 doi: 10.1021/bi00489a001
[25]
Schreiber G, Buckle AM, Fersht AR. Stability and function: two constraints in the evolution of barstar and other proteins. Structure. 1994;2: 945–951. pmid:7866746 doi: 10.1016/s0969-2126(94)00096-4
[26]
Shoichet BK, Baase WA, Kuroki R, Matthews BW. A relationship between protein stability and protein function. Proc Natl Acad Sci U S A. 1995;92: 452–456. pmid:7831309 doi: 10.1073/pnas.92.2.452
[27]
Wang X, Minasov G, Shoichet BK. Evolution of an Antibiotic Resistance Enzyme Constrained by Stability and Activity Trade-offs. J Mol Biol. 2002;320: 85–95. pmid:12079336 doi: 10.1016/s0022-2836(02)00400-x
[28]
Brown NG, Pennington JM, Huang W, Ayvaz T, Palzkill T. Multiple global suppressors of protein stability defects facilitate the evolution of extended-spectrum TEM β-lactamases. J Mol Biol. 2010;404: 832–846. doi: 10.1016/j.jmb.2010.10.008. pmid:20955714
[29]
Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31: 455–461. doi: 10.1002/jcc.21334. pmid:19499576
[30]
Ke W, Bethel CR, Thomson JM, Bonomo RA, van den Akker F. Crystal structure of KPC-2: insights into carbapenemase activity in class A β-lactamases. Biochemistry. 2007;46: 5732–5740. pmid:17441734 doi: 10.1021/bi700300u
[31]
Sowek JA, Singer SB, Ohringer S, Malley MF, Dougherty TJ, Gougoutas JZ, et al. Substitution of lysine at position 104 or 240 of TEM-1pTZ18R beta-lactamase enhances the effect of serine-164 substitution on hydrolysis or affinity for cephalosporins and the monobactam aztreonam. Biochemistry. 1991;30: 3179–3188. pmid:1901218 doi: 10.1021/bi00227a004
[32]
Cantu C 3rd, Huang W, Palzkill T. Cephalosporin substrate specificity determinants of TEM-1 β-lactamase. J Biol Chem. 1997;272: 29144–29150. pmid:9360991 doi: 10.1074/jbc.272.46.29144
[33]
Petit A, Maveyraud L, Lenfant F, Samama JP, Labia R, Masson JM. Multiple substitutions at position 104 of β-lactamase TEM-1: assessing the role of this residue in substrate specificity. Biochem J. 1995;305 (Pt 1): 33–40. pmid:7826350
[34]
Bonnet R, Recule C, Baraduc R, Chanal C, Sirot D, De Champs C, et al. Effect of D240G substitution in a novel ESBL CTX-M-27. J Antimicrob Chemother. 2003;52: 29–35. pmid:12775683 doi: 10.1093/jac/dkg256
[35]
Brown NG, Pennington JM, Huang W, Ayvaz T, Palzkill T. Multiple Global Suppressors of Protein Stability Defects Facilitate the Evolution of Extended-Spectrum TEM β-Lactamases. J Mol Biol. 2010;404: 832–846. doi: 10.1016/j.jmb.2010.10.008. pmid:20955714
[36]
Meiering EM, Serrano L, Fersht AR. Effect of active site residues in barnase on activity and stability. J Mol Biol. 1992;225: 585–589. pmid:1602471 doi: 10.1016/0022-2836(92)90387-y
[37]
Chen Y, Delmas J, Sirot J, Shoichet B, Bonnet R. Atomic resolution structures of CTX-M β-lactamases: extended spectrum activities from increased mobility and decreased stability. J Mol Biol. 2005;348: 349–362. pmid:15811373 doi: 10.1016/j.jmb.2005.02.010
[38]
Huang W, Palzkill T. A natural polymorphism in β-lactamase is a global suppressor. Proc Natl Acad Sci U S A. 1997;94: 8801–8806. pmid:9238058 doi: 10.1073/pnas.94.16.8801
[39]
Bloom JD, Arnold FH. In the light of directed evolution: pathways of adaptive protein evolution. Proc Natl Acad Sci U S A. 2009;106 Suppl 1: 9995–10000. doi: 10.1073/pnas.0901522106. pmid:19528653
[40]
Bloom JD, Silberg JJ, Wilke CO, Drummond DA, Adami C, Arnold FH. Thermodynamic prediction of protein neutrality. Proc Natl Acad Sci U S A. 2005;102: 606–611. pmid:15644440 doi: 10.1073/pnas.0406744102
[41]
Besenmatter W, Kast P, Hilvert D. Relative tolerance of mesostable and thermostable protein homologs to extensive mutation. Proteins. 2007;66: 500–506. pmid:17096428 doi: 10.1002/prot.21227
[42]
Bloom JD, Labthavikul ST, Otey CR, Arnold FH. Protein stability promotes evolvability. Proc Natl Acad Sci U S A. 2006;103: 5869–5874. pmid:16581913 doi: 10.1073/pnas.0510098103
[43]
Wang D, Chen J, Yang L, Mou Y, Yang Y. Phenotypic and enzymatic comparative analysis of the KPC variants, KPC-2 and its recently discovered variant KPC-15. PLoS One. 2014;9: e111491. doi: 10.1371/journal.pone.0111491. pmid:25360633
[44]
Datta N, Kontomichalou P. Penicillinase synthesis controlled by infectious R factors in Enterobacteriaceae. Nature. 1965;208: 239–241. pmid:5326330 doi: 10.1038/208239a0
[45]
Amann E, Brosius J, Ptashne M. Vectors bearing a hybrid trp-lac promoter useful for regulated expression of cloned genes in Escherichia coli. Gene. 1983;25: 167–178. pmid:6363212 doi: 10.1016/0378-1119(83)90222-6
[46]
Petrosino J, Rudgers G, Gilbert H, Palzkill T. Contributions of aspartate 49 and phenylalanine 142 residues of a tight binding inhibitory protein of β-lactamases. J Biol Chem. 1999;274: 2394–2400. pmid:9891008 doi: 10.1074/jbc.274.4.2394
[47]
Brown NG, Chow DC, Palzkill T. BLIP-II is a highly potent inhibitor of Klebsiella pneumoniae carbapenemase (KPC-2). Antimicrob Agents Chemother. 2013;57: 3398–3401. doi: 10.1128/AAC.00215-13. pmid:23587951
[48]
Artimo P, Jonnalagedda M, Arnold K, Baratin D, Csardi G, de Castro E, et al. ExPASy: SIB bioinformatics resource portal. Nucleic Acids Res. 2012;40: W597–603. doi: 10.1093/nar/gks400. pmid:22661580
[49]
Dunbrack RL Jr. Rotamer libraries in the 21st century. Curr Opin Struct Biol. 2002;12: 431–440. pmid:12163064 doi: 10.1016/s0959-440x(02)00344-5
[50]
Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, et al. UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem. 2004;25: 1605–1612. pmid:15264254 doi: 10.1002/jcc.20084
[51]
Stojanoski V, Chow DC, Hu L, Sankaran B, Gilbert HF, Prasad BV, et al. A Triple Mutant in the Ω-loop of TEM-1 β-Lactamase Changes the Substrate Profile via a Large Conformational Change and an Altered General Base for Catalysis. J Biol Chem. 2015;290: 10382–10394. doi: 10.1074/jbc.M114.633438. pmid:25713062
